Beginning Cash: The amount of cash reported by the company on its previous statement.
Alto Neuroscience, Inc. (ANRO) had Beginning Cash of $168.73M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-14.18M |
|
-- |
|
-- |
|
$14.95M |
|
$-14.95M |
|
$0.77M |
|
$-14.18M |
|
$-14.18M |
|
$-14.18M |
|
$-14.18M |
|
$-14.18M |
|
$-14.18M |
|
$-14.95M |
|
$-14.79M |
|
27.10M |
|
27.10M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$139.45M |
|
$2.03M |
|
$7.56M |
|
$147.01M |
|
$9.04M |
|
$22.44M |
|
$26.40M |
|
$35.45M |
|
$111.56M |
|
$111.56M |
|
$111.56M |
|
27.17M |
|
| Cash Flow Statement Financials | |
$-40.25M |
|
$-0.02M |
|
$9.89M |
|
|
Beginning Cash |
$168.73M |
$138.32M |
|
$-30.41M |
|
$6.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.42 |
|
-- |
|
-- |
|
0.17 |
|
0.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-40.28M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.71% |
|
-12.71% |
|
-9.65% |
|
-10.58% |
|
$4.11 |
|
$-1.49 |
|
$-1.49 |
|